Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SRDX's Cash to Debt is ranked higher than
91% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. SRDX: No Debt )
SRDX' s 10-Year Cash to Debt Range
Min: 50.6   Max: No Debt
Current: No Debt

Equity to Asset 0.94
SRDX's Equity to Asset is ranked higher than
98% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. SRDX: 0.94 )
SRDX' s 10-Year Equity to Asset Range
Min: 0.74   Max: 0.96
Current: 0.94

0.74
0.96
Interest Coverage No Debt
SRDX's Interest Coverage is ranked higher than
79% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 127.94 vs. SRDX: No Debt )
SRDX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 8
Z-Score: 37.24
M-Score: -3.02
WACC vs ROIC
13.66%
22.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 33.38
SRDX's Operating margin (%) is ranked higher than
99% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. SRDX: 33.38 )
SRDX' s 10-Year Operating margin (%) Range
Min: -20.11   Max: 51.75
Current: 33.38

-20.11
51.75
Net-margin (%) 20.80
SRDX's Net-margin (%) is ranked higher than
99% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. SRDX: 20.80 )
SRDX' s 10-Year Net-margin (%) Range
Min: -35.08   Max: 32.59
Current: 20.8

-35.08
32.59
ROE (%) 13.21
SRDX's ROE (%) is ranked higher than
89% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. SRDX: 13.21 )
SRDX' s 10-Year ROE (%) Range
Min: -12.91   Max: 23.9
Current: 13.21

-12.91
23.9
ROA (%) 12.43
SRDX's ROA (%) is ranked higher than
95% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.94 vs. SRDX: 12.43 )
SRDX' s 10-Year ROA (%) Range
Min: -11.85   Max: 19.94
Current: 12.43

-11.85
19.94
ROC (Joel Greenblatt) (%) 105.51
SRDX's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. SRDX: 105.51 )
SRDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -18.72   Max: 154.38
Current: 105.51

-18.72
154.38
Revenue Growth (3Y)(%) 11.10
SRDX's Revenue Growth (3Y)(%) is ranked higher than
86% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. SRDX: 11.10 )
SRDX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -24.6   Max: 57.8
Current: 11.1

-24.6
57.8
EBITDA Growth (3Y)(%) 12.70
SRDX's EBITDA Growth (3Y)(%) is ranked higher than
85% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. SRDX: 12.70 )
SRDX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -32.6   Max: 92.2
Current: 12.7

-32.6
92.2
EPS Growth (3Y)(%) 11.80
SRDX's EPS Growth (3Y)(%) is ranked higher than
85% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.60 vs. SRDX: 11.80 )
SRDX' s 10-Year EPS Growth (3Y)(%) Range
Min: -35.4   Max: 46.8
Current: 11.8

-35.4
46.8
» SRDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SRDX Guru Trades in Q1 2014

Mario Gabelli 33,300 sh (+113.23%)
Jim Simons 510,395 sh (+12.14%)
Chuck Royce 733,300 sh (unchged)
Joel Greenblatt Sold Out
Bill Frels 739,540 sh (-0.82%)
» More
Q2 2014

SRDX Guru Trades in Q2 2014

Mario Gabelli 130,778 sh (+292.73%)
Chuck Royce 744,800 sh (+1.57%)
Bill Frels 738,470 sh (-0.14%)
Jim Simons 504,238 sh (-1.21%)
» More
Q3 2014

SRDX Guru Trades in Q3 2014

Mario Gabelli 185,398 sh (+41.77%)
Chuck Royce 744,800 sh (unchged)
Jim Simons 501,938 sh (-0.46%)
Bill Frels 728,390 sh (-1.36%)
» More
Q4 2014

SRDX Guru Trades in Q4 2014

Jim Simons 582,738 sh (+16.1%)
Chuck Royce 718,400 sh (-3.54%)
Mario Gabelli 120,398 sh (-35.06%)
Bill Frels 40,790 sh (-94.4%)
» More
» Details

Insider Trades

Latest Guru Trades with SRDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2014-12-31 Reduce -35.06%0.01%$19.55 - $22.61 $ 24.0513%120398
Mario Gabelli 2014-09-30 Add 41.77%0.01%$18.12 - $22.4 $ 24.0520%185398
Mario Gabelli 2014-06-30 Add 292.73%0.01%$19.85 - $23.37 $ 24.0512%130778
Joel Greenblatt 2014-03-31 Sold Out 0.03%$22.14 - $25.79 $ 24.05-2%0
Mario Gabelli 2014-03-31 Add 113.23%$22.14 - $25.79 $ 24.05-2%33300
Mario Gabelli 2013-12-31 New Buy$21.61 - $25.135 $ 24.052%15617
Joel Greenblatt 2013-06-30 Add 38.66%0.01%$19.74 - $27.55 $ 24.05-4%59954
Joel Greenblatt 2012-12-31 Reduce -25.79%0.03%$17.45 - $22.03 $ 24.0521%53262
Joel Greenblatt 2012-12-31 Reduce -25.79%0.03%$17.45 - $22.03 $ 24.0521%53262
Joel Greenblatt 2012-09-30 Add 60.21%0.04%$15.38 - $20.78 $ 24.0534%71768
Mario Gabelli 2012-09-30 Sold Out 0.03%$15.38 - $20.78 $ 24.0534%0
PRIMECAP Management 2012-06-30 Sold Out 0.0015%$13.6 - $17.22 $ 24.0561%0
Joel Greenblatt 2012-03-31 Add 200.69%0.04%$13.86 - $16.06 $ 24.0575%44610
Richard Snow 2012-03-31 Sold Out 0.02%$13.86 - $16.06 $ 24.0575%0
Joel Greenblatt 2011-12-31 New Buy0.03%$8.86 - $14.99 $ 24.05111%14836
Richard Snow 2011-12-31 Add 48.24%0.01%$8.86 - $14.99 $ 24.05111%24659
PRIMECAP Management 2011-12-31 Reduce -73.57%$8.86 - $14.99 $ 24.05111%66000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 27.40
SRDX's P/E(ttm) is ranked higher than
90% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 27.40 )
SRDX' s 10-Year P/E(ttm) Range
Min: 8.5   Max: 687.94
Current: 27.4

8.5
687.94
Forward P/E 23.58
SRDX's Forward P/E is ranked higher than
87% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 23.58 )
N/A
PE(NRI) 26.70
SRDX's PE(NRI) is ranked higher than
90% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 26.70 )
SRDX' s 10-Year PE(NRI) Range
Min: 8.52   Max: 668.29
Current: 26.7

8.52
668.29
P/B 3.79
SRDX's P/B is ranked higher than
73% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.00 vs. SRDX: 3.79 )
SRDX' s 10-Year P/B Range
Min: 0.98   Max: 7.77
Current: 3.79

0.98
7.77
P/S 5.71
SRDX's P/S is ranked higher than
67% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.52 vs. SRDX: 5.71 )
SRDX' s 10-Year P/S Range
Min: 2.16   Max: 13.8
Current: 5.71

2.16
13.8
PFCF 18.64
SRDX's PFCF is ranked higher than
94% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 18.64 )
SRDX' s 10-Year PFCF Range
Min: 8.44   Max: 511.5
Current: 18.64

8.44
511.5
POCF 16.70
SRDX's POCF is ranked higher than
89% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 16.70 )
SRDX' s 10-Year POCF Range
Min: 5.96   Max: 36.68
Current: 16.7

5.96
36.68
EV-to-EBIT 14.56
SRDX's EV-to-EBIT is ranked higher than
93% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 14.56 )
SRDX' s 10-Year EV-to-EBIT Range
Min: -47.4   Max: 253.6
Current: 14.56

-47.4
253.6
Shiller P/E 142.73
SRDX's Shiller P/E is ranked higher than
83% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 142.73 )
SRDX' s 10-Year Shiller P/E Range
Min: 16.9   Max: 158.8
Current: 142.73

16.9
158.8
Current Ratio 11.03
SRDX's Current Ratio is ranked higher than
95% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. SRDX: 11.03 )
SRDX' s 10-Year Current Ratio Range
Min: 1.57   Max: 18.27
Current: 11.03

1.57
18.27
Quick Ratio 10.23
SRDX's Quick Ratio is ranked higher than
95% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. SRDX: 10.23 )
SRDX' s 10-Year Quick Ratio Range
Min: 1.49   Max: 18
Current: 10.23

1.49
18
Days Inventory 130.39
SRDX's Days Inventory is ranked higher than
69% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 128.32 vs. SRDX: 130.39 )
SRDX' s 10-Year Days Inventory Range
Min: 33.96   Max: 234.64
Current: 130.39

33.96
234.64
Days Sales Outstanding 28.07
SRDX's Days Sales Outstanding is ranked higher than
95% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 81.46 vs. SRDX: 28.07 )
SRDX' s 10-Year Days Sales Outstanding Range
Min: 28.08   Max: 80.51
Current: 28.07

28.08
80.51

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.28
SRDX's Price/Net Cash is ranked higher than
90% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 12.28 )
SRDX' s 10-Year Price/Net Cash Range
Min: 3.9   Max: 700
Current: 12.28

3.9
700
Price/Net Current Asset Value 10.32
SRDX's Price/Net Current Asset Value is ranked higher than
88% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 10.32 )
SRDX' s 10-Year Price/Net Current Asset Value Range
Min: 3.7   Max: 763
Current: 10.32

3.7
763
Price/Tangible Book 4.36
SRDX's Price/Tangible Book is ranked higher than
81% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.30 vs. SRDX: 4.36 )
SRDX' s 10-Year Price/Tangible Book Range
Min: 1.26   Max: 18.49
Current: 4.36

1.26
18.49
Price/DCF (Projected) 1.78
SRDX's Price/DCF (Projected) is ranked higher than
91% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 1.78 )
SRDX' s 10-Year Price/DCF (Projected) Range
Min: 0.53   Max: 4.59
Current: 1.78

0.53
4.59
Price/Median PS Value 0.90
SRDX's Price/Median PS Value is ranked higher than
89% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. SRDX: 0.90 )
SRDX' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 7.62
Current: 0.9

0.39
7.62
Price/Graham Number 2.22
SRDX's Price/Graham Number is ranked higher than
92% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 2.22 )
SRDX' s 10-Year Price/Graham Number Range
Min: 0.9   Max: 12.63
Current: 2.22

0.9
12.63
Earnings Yield (Greenblatt) 6.90
SRDX's Earnings Yield (Greenblatt) is ranked higher than
93% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. SRDX: 6.90 )
SRDX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 22
Current: 6.9

0.4
22
Forward Rate of Return (Yacktman) 22.44
SRDX's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.60 vs. SRDX: 22.44 )
SRDX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.1   Max: 61.9
Current: 22.44

1.1
61.9

Analyst Estimate

Sep15 Sep16 Sep17
Revenue(Mil) 59 61 71
EPS($) 0.94 1.00 1.18
EPS without NRI($) 0.94 1.00 1.18

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
SurModics, Inc. was organized as a Minnesota corporation in June 1979. The Company is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company's core offerings include surface modification coating technologies that impart lubricity, prohealing, and biocompatibility characteristics and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. It partners with many of the emerging medical device, pharmaceutical and life science companies to develop and commercialize innovative products designed to improve patient outcomes. Although its drug delivery and surface modification technologies themselves are not directly regulated by the Food and Drug Administration, the medical devices, pharmaceutical and biotechnology products incorporating its technologies are subject to FDA regulation.
» More Articles for SRDX

Headlines

Articles On GuruFocus.com
SurModics Inc. Reports Operating Results (10-Q) Aug 06 2010 
SurModics Inc. Reports Operating Results (10-Q) May 07 2010 
SurModics Inc. Reports Operating Results (10-Q) Feb 05 2010 
SurModics Inc. Reports Operating Results (10-K) Dec 11 2009 
SurModics Inc. (SRDX) Senior VP & CFO Philip D Ankeny sells 5,000 Shares Oct 08 2009 
SurModics Inc. Reports Operating Results (10-Q) Aug 07 2009 
SurModics Inc. Reports Operating Results (10-Q) May 08 2009 
SurModics Inc. Reports Operating Results (10-Q) Feb 09 2009 
SurModics Reports First Quarter 2009 Results Jan 28 2009 
SurModics to Webcast Fiscal 2009 First Quarter Earnings Conference Call January 28 Jan 14 2009 

More From Other Websites
SurModics to Present at RBC Capital Markets Global Healthcare Conference Feb 19 2015
SurModics to Present at RBC Capital Markets Global Healthcare Conference Feb 19 2015
SURMODICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters... Feb 13 2015
SURMODICS INC Financials Feb 11 2015
10-Q for SurModics, Inc. Feb 06 2015
SURMODICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Feb 05 2015
SurModics Announces Gerald B. Fischer’s Retirement from Board of Directors Feb 05 2015
SurModics Announces Gerald B. Fischer’s Retirement from Board of Directors Feb 05 2015
SURMODICS INC Files SEC form 10-Q, Quarterly Report Feb 04 2015
SurModics to Webcast Shareholders Annual Meeting on February 10 Feb 03 2015
SurModics, Inc. (SRDX): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Feb 02 2015
SurModics Beats on Q1 Earnings, Reaffirms 2015 Guidance - Analyst Blog Jan 30 2015
SurModics beats 1Q profit forecasts Jan 29 2015
SurModics beats 1Q profit forecasts Jan 29 2015
SurModics Inc Earnings Call scheduled for 5:00 pm ET today Jan 29 2015
SURMODICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jan 29 2015
SurModics Reports First Quarter Fiscal 2015 Results Jan 29 2015
SurModics Reports First Quarter Fiscal 2015 Results Jan 29 2015
Q1 2015 SurModics Inc Earnings Release - After Market Close Jan 29 2015
SurModics to Webcast First Quarter 2015 Earnings Conference Call on January 29 Jan 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK